secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001390478-25-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS reports FY2024 net loss $30.9M; Phase 3 REGAL trial interim analysis positive
--------------------------------------------------------------------------------

- Net loss $30.9M ($0.50/share) vs $37.3M ($1.34) in FY2023; R&D expenses down to $19.1M.
- Cash $13.9M at Dec 31, 2024; raised $25M in January 2025 registered direct offering.
- Positive interim analysis for Phase 3 REGAL trial (GPS in AML); final analysis expected upon 80 events in 2025.
- Phase 2 SLS009 in r/r AML: 56% ORR in AML-MRC cohorts; median OS >7.7 months vs historic ~2.5 months.
- Received multiple regulatory designations: three FDA RPDD, one Fast Track, two EMA ODD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/0001390478-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001390478-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer